Lisata Seeks Stockholder Approval for Marea Conversion, Reverse Split to Avoid Nasdaq Delisting
LSTA sits 18% above its 52-week low of $0.988.
Summary
Lisata's preliminary proxy seeks approval to convert Series C Preferred Stock and execute a 1-for-5 to 1-for-10 reverse split to satisfy Nasdaq's initial listing requirements after the Marea acquisition. Failure to approve could trigger cash settlement obligations and delisting.
Key Events · Corporate Governance and Compliance · LSTA
-
Stockholder Vote on Series C Conversion
Annual meeting set for November 9, 2026 to approve conversion of 362,233.208 Series C Preferred shares into 385,034,614 common shares, representing over 20% of outstanding stock and a Nasdaq-defined change of control.
-
Reverse Split Required for Nasdaq Listing
Nasdaq notified the company on September 25, 2026 that the Marea deal triggers initial listing requirements, including a $4.00 minimum bid price. The proposed 1-for-5 to 1-for-10 reverse split is designed to meet this threshold.
-
Cash Settlement Risk
If Required Company Stockholder Matters are not approved by March 17, 2027, Series C holders can require cash settlement at fair value of the underlying common stock, a potentially material obligation.
-
New Equity Plans Proposed
The 2026 Equity Incentive Plan reserves 44,764,472 shares and the 2026 ESPP reserves 3,730,372 shares, replacing prior plans and adding potential future dilution.
Analysis · LSTA · Life Sciences
The proxy statement reveals that the completed Marea acquisition and $225M PIPE hinge on stockholder approval of Series C conversion and a reverse stock split. Nasdaq has already flagged the deal as a change of control requiring initial listing approval, and the stock trades below the $4.00 minimum bid price. If stockholders reject the proposals, Series C holders can force cash settlement at fair value after March 17, 2027 — a potentially crippling obligation for a company with a going-concern history. The reverse split is not optional; it is the mechanism to keep the combined company listed.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 36.9% of the 1029 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.77%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LSTA was trading at $1.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.5M. The 52-week trading range was $0.99 to $5.07. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.